We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Genzyme Hits Impax With IP Suit Over Renagel ANDA

Law360 (March 17, 2009, 12:00 AM EDT) -- Biotechnology company Genzyme Corp. has filed its second patent infringement lawsuit this month to block a generic version of the drug Renagel, this time targeting California-based generics maker Impax Laboratories Inc.

Genzyme filed the lawsuit Monday in the U.S. District Court for the District of Maryland, claiming that Impax’s proposed generic sevelamer hydrochloride tablets would infringe U.S. Patent Number 5,667,775.

Cambridge, Mass.-based Genzyme fired off the lawsuit shortly after receiving a notification letter on Jan. 27 from Impax alerting the plaintiff that it had filed an...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.